Alzheimer-kór: vizsgálatok itt: Chile
10 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
- Where
- Santiago
- Életkor
- 55 év to 80 év
- People
- 1600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07717411 - 2/3. fázisTaking peopleACP-204 in Adults With Alzheimer's Disease Psychosis
- Where
- Antofagasta, Santiago
- Életkor
- 55 év to 95 év
- People
- 1074 worldwide
- Run by
- ACADIA Pharmaceuticals Inc.
See details and how to joinNCT06159673 · EU 2023-507325-42-00 - 3. fázisCsak meghívásosACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
- Where
- Antofagasta, Santiago
- Életkor
- 55 év to 95 év
- People
- 752 worldwide
- Run by
- ACADIA Pharmaceuticals Inc.
See details and how to joinNCT06194799 · EU 2023-507351-29-00 - 3. fázisTaking peopleA Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
- Where
- Antofagasta, Santiago, Viña del Mar, Vitacura
- Életkor
- 55 év to 90 év
- People
- 426 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07011745 · EU 2025-520612-34-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
- Where
- Antofagasta, Santiago
- Életkor
- 60 év to 85 év
- People
- 586 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06976216 · EU 2025-520746-30-00 - 3. fázisTaking peopleScreening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
- Where
- Santiago, Valdivia
- Életkor
- 50 év to 90 év
- People
- 80 000 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07177352 - 3. fázisTaking peopleOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
- Where
- Antofagasta, Las Condes, Providencia
- Életkor
- 55 év to 90 év
- People
- 1000 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00 - 3. fázisTaking peopleA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
- Where
- Antofagasta, Las Condes, Providencia
- Életkor
- 55 év to 90 év
- People
- 500 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06126224 · EU 2023-504416-16-00 - 3. fázisTaking peopleA Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
- Where
- Antofagasta, Santiago, Viña del Mar, Vitacura
- Életkor
- 55 év to 90 év
- People
- 650 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00 - 2. fázisTaking peopleA Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
- Where
- Antofagasta, Santiago
- Életkor
- 55 év to 90 év
- People
- 300 worldwide
- Run by
- MapLight Therapeutics
See details and how to joinNCT06887192 · EU 2024-519820-26-00